

=> "carcinoembryonic antigen" or EAC
L1 17768 "CARCINOEMBRYONIC ANTIGEN" OR EAC

=> CD40
L2 11683 CD40

=> L1 and L2
L3 46 L1 AND L2

=> DNA (1) L3
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'DNA (L) L7'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'DNA (L) L8'
L4 22 DNA (L) L3

=> plasmid (1) L3
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'PLASMID (L) L7'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'PLASMID (L) L8'
L5 7 PLASMID (L) L3

L3 ANSWER 39 OF 46 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:484479 CAPLUS

DOCUMENT NUMBER: 129:201867

TITLE: Optimization of the sequence of antigen loading and
CD40-ligand-induced maturation of dendritic
cells

AUTHOR(S): Morse, Michael A.; Lysterly, H. Kim; Gilboa, Eli;
Thomas, Elaine; Nair, Smita K.

CORPORATE SOURCE: Department of Medicine, Duke University Medical
Center, Durham, NC, 27710, USA

SOURCE: Cancer Research (1998), 58(14), 2965-2968
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

TI Optimization of the sequence of antigen loading and CD40
-ligand-induced maturation of dendritic cells

SO Cancer Research (1998), 58(14), 2965-2968
CODEN: CNREA8; ISSN: 0008-5472

AU Morse, Michael A.; Lysterly, H. Kim; Gilboa, Eli; Thomas, Elaine; Nair,
Smita K.

AB Dendritic cells (DCs), matured by CD40-ligand (CD40L), undergo
marked changes in their ability to process and present antigen, resulting
in augmented lymphocyte stimulatory activity. The authors demonstrate
that the form of the tumor antigen (peptide or genetic material) used to
load the DCs dictates the required sequence of antigen loading and
maturation for antitumor immunotherapy. Optimal stimulation of
carcinoembryonic antigen (CEA)-specific CTLs by
peptide-loaded DCs occurs when DCs from cancer patients are matured with
CD40L before exposure to CEA peptide, whereas optimal stimulation by
RNA-transfected DCs occurs when the DCs are loaded with CEA RNA before
maturation with CD40L.

L3 ANSWER 44 OF 46 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 ACCESSION NUMBER: 2001:513002 BIOSIS
 DOCUMENT NUMBER: PREV200100513002
 TITLE: DNA vaccines encoding a **CD40** ligand-trimer-CEA
 chimeric protein combined with boosts of an antibody-IL2
 fusion protein markedly enhanced tumor protective immunity
 in CEA-transgenic mice.
 AUTHOR(S): Xiang, R. [Reprint author]; Silletti, S.; Lode, H. N.;
 Dolman, C. S.; Ruehlmann, J. M.; Niethammer, A. G.; Ba, Y.;
 Gillies, S. D.; Primus, F. J.; Reisfeld, R. A.
 CORPORATE SOURCE: Lexigen Pharmaceuticals, Lexington, MA, USA
 SOURCE: Proceedings of the American Association for Cancer Research
 Annual Meeting, (March, 2001) Vol. 42, pp. 698-699. print.
 Meeting Info.: 92nd Annual Meeting of the American
 Association for Cancer Research. New Orleans, LA, USA.
 March 24-28, 2001.
 ISSN: 0197-016X.
 DOCUMENT TYPE: Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 31 Oct 2001
 Last Updated on STN: 23 Feb 2002
 TI DNA vaccines encoding a **CD40** ligand-trimer-CEA chimeric protein
 combined with boosts of an antibody-IL2 fusion protein markedly enhanced
 tumor protective immunity in CEA-transgenic mice.
 SO Proceedings of the American Association for Cancer Research Annual
 Meeting, (March, 2001) Vol. 42, pp. 698-699. print.
 Meeting Info.: 92nd Annual Meeting of the American Association for Cancer
 Research. New Orleans, LA, USA. March 24-28, 2001.
 ISSN: 0197-016X.
 AU Xiang, R. [Reprint author]; Silletti, S.; Lode, H. N.; Dolman, C. S.;
 Ruehlmann, J. M.; Niethammer, A. G.; Ba, Y.; Gillies, S. D.; Primus, F.
 J.; Reisfeld, R. A.